Page 24 - Read Online

Kirakli et al. J Cancer Metastasis Treat 2019;5:10 I http://dx.doi.org/10.20517/2394-4722.2018.73 Page 11 of 12

jamaoncol.2018.4610. .
23. Kelly PJ, Lin YB, Yu AY, Alexander BM, Hacker F, et al. Stereotactic irradiation of the postoperative resection cavity for brain metastasis: a
frameless linear accelerator-based case series and review of the technique. Int J Radiat Oncol Biol Phys 2012;82:95-101.
24. Soltys SG, Adler JR, Lipani JD, Jackson PS, Choi CY, et al. Stereotactic radiosurgery of the postoperative resection cavity for brain
metastases. Int J Radiat Oncol Biol Phys 2008;70:187-93.
25. Brennan C, Yang TJ, Hilden P, Zhang Z, Chan K, et al. A phase 2 trial of stereotactic radiosurgery boost after surgical resection for brain
metastases. Int J Radiat Oncol Biol Phys 2014;88:130-6.
26. Kępka L, Tyc-Szczepaniak D, Bujko K, Olszyna-Serementa M, Michalski W, et al. Stereotactic radiotherapy of the tumor bed compared to
whole brain radiotherapy after surgery of single brain metastasis: results from a randomized trial. Radiother Oncol 2016;121:217-24.
27. Atalar B, Modlin LA, Choi CY, Adler JR, Gibbs IC, et al. Risk of leptomeningeal disease in patients treated with stereotactic radiosurgery
targeting the postoperative resection cavity for brain metastases. Int J Radiat Oncol Biol Phys 2013;87:713-8.
28. Johnson MD, Avkshtol V, Baschnagel AM, Meyer K, Ye H, et al. Surgical resection of brain metastases and the risk of leptomeningeal
recurrence in patients treated with stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 2016;94:537-43.
29. Soliman H, Ruschin M, Angelov L, Brown PD, Chiang VLS, et al. Consensus contouring guidelines for postoperative completely resected
cavity stereotactic radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys 2018;100:436-42.
30. Patel KR, Burri SH, Boselli D, Symanowski JT, Asher AL, et al. Comparing pre-operative stereotactic radiosurgery (SRS) to post-operative
whole brain radiation therapy (WBRT) for resectable brain metastases: a multi-institutional analysis. J Neurooncol 2017;131:611-8.
31. NRG Oncology. NRG Oncology Semiannual Meeting 2016. Available from: https://www.nrgoncology.org/LinkClick.aspx?fileticket=TTkE
Mgz9_7U%3D&portalid=0. [Last accessed on 17 Jan 2019]
32. Sperduto PW, Shanley R, Luo X, Andrews D, Werner-Wasik M, et al. Secondary analysis of RTOG 9508, a phase 3 randomized trial of
whole-brain radiation therapy versus WBRT plus stereotactic radiosurgery in patients with 1-3 brain metastases; poststratified by the graded
prognostic assessment (GPA). Int J Radiat Oncol Biol Phys 2014;90:526-31.
33. Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic
radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 2006;295:2483-91.
34. Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, et al. Neurocognition in patients with brain metastases treated with radiosurgery or
radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 2009;10:1037-44.
35. Kocher M, Soffietti R, Abacioglu U, Villà S, Fauchon F, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or
surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 2011;29:134-41.
36. Tsao M, Xu W, Sahgal A. A meta-analysis evaluating stereotactic radiosurgery, whole-brain radiotherapy, or both for patients presenting
with a limited number of brain metastases. Cancer 2012;118:2486-93.
37. Brown PD, Jaeckle K, Ballman KV, Farace E, Cerhan JH, et al. Effect of radiosurgery alone vs radiosurgery with whole brain radiation
therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. JAMA 2016;316:401-9.
38. Aoyama H, Tago M, Shirato H; Japanese Radiation Oncology Study Group 99-1 (JROSG 99-1) Investigators. Stereotactic radiosurgery with
or without whole-brain radiotherapy for brain metastases: secondary analysis of the JROSG 99-1 randomized clinical trial. JAMA Oncol
2015;1:457-64.
39. Churilla TM, Handorf E, Collette S, Collette L, Dong Y, et al. Whole brain radiotherapy after stereotactic radiosurgery or surgical resection
among patients with one to three brain metastases and favorable prognoses: a secondary analysis of EORTC 22952-26001. Ann Oncol
2017;28:2588-94.
40. Sahgal A, Aoyama H, Kocher M, Neupane B, Collette S, et al. Phase 3 trials of stereotactic radiosurgery with or without whole-brain
radiation therapy for 1 to 4 brain metastases: individual patient data meta-analysis. Int J Radiat Oncol Biol Phys 2015;91:710-7.
41. Churilla TM, Ballman KV, Brown PD, Twohy EL, Jaeckle K, et al. Stereotactic radiosurgery with or without whole-brain radiation therapy
for limited brain metastases: a secondary analysis of the North Central Cancer Treatment Group N0574 (Alliance) randomized controlled
trial. Int J Radiat Oncol Biol Phys2017;99:1173-8.
42. Aoyama H, Tago M, Kato N, Toyoda T, Kenjyo M, et al. Neurocognitive function of patients with brain metastasis who received either
whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. Int J Radiat Oncol Biol Phys 2007;68:1388-95.
43. Meyers CA, Wefel JS. The use of the mini-mental state examination to assess cognitive functioning in cancer trials: no ifs, ands, buts, or
sensitivity. J Clin Oncol 2003;21:3557-8.
44. Soffietti R, Kocher M, Abacioglu UM, Villa S, Fauchon F, et al. A European Organisation for Research and Treatment of Cancer phase III
trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical
resection or radiosurgery: quality-of-life results. J Clin Oncol 2013;31:65-72.
45. ASTRO Update. Ten things physicians and patients should question. Available from: https://www.reproductivefacts.org/news-and-
publications/choosing-wisely2/. [Last accessed on 24 Jan 2019]
46. Meyers CA, Smith JA, Bezjak A, Mehta MP, Liebmann J, et al. Neurocognitive function and progression in patients with brain metastases
treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol 2004;22:157-65.
47. Regine WF, Huhn JL, Patchell RA, St Clair WH, Strottmann J, et al. Risk of symptomatic brain tumor recurrence and neurologic deficit after
radiosurgery alone in patients with newly diagnosed brain metastases: results and implications. Int J Radiat Oncol Biol Phys 2002;52:333-8.
48. Tsao MN, Rades D, Wirth A, Lo SS, Danielson BL, et al. Radiotherapeutic and surgical management for newly diagnosed brain
metastasis(es): an American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol 2012;2:210-25.
49. Mulvenna P, Nankivell M, Barton R, Faivre-Finn C, Wilson P, et al. Dexamethasone and supportive care with or without whole brain
radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy
(QUARTZ): results from a phase 3, non-inferiority, randomised trial. Lancet 2016;388:2004-14.
50. Gondi V, Hermann BP, Mehta MP, Tomé WA. Hippocampal dosimetry predicts neurocognitive function impairment after fractionated
stereotactic radiotherapy for benign or low-grade adult brain tumors. Int J Radiat Oncol Biol Phys 2013;85:348-54.